I
Blume MR, Rosenbaum EH, Cohen RJ, Gershow J, Glassberg AB, Shepley E.
100 I
III 1.0 .
96 15 - 67 (: 30 ) .
( ), . 5- 99%.
46 ( ), , 63%, 5- 69%. . , I.
---------------------------------------------------------------------------------------------------------------------------
1996 BIOTHERAPY 9(1-3):123-132
Pizza G; DeVinci C; Cuzzocrea D; Menniti D; Aiello E; Maver P; Corrado G; Romagnoli P; Dragoni E; LoConte G; Riolo U; Palareti A; Zucchelli P; Fornarola V; Viza D
A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer
As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.
- III .
III , .
, (CMI) (TAA).
. 50 III . 2-5- . , 1 9 , , , 6, - 14 . 126 , , .
|
|
|
Laryngoscope 1978 Jan;88(1 Pt 2 Suppl 8):79-82
Transference of cell mediated immunity in patients with head and neck cancer
Vetto RM, Burger DR.
A group of 67 patients with head and neck cancer has been studied of which 40 have received immunologic transfer factor from a normal donor pool. Examination of these patients revealed that lymphocyte reactivity to nonspecific mitogrens is depressed in patients who have head and neck cancer to a much greater extent than is seen in patients with other types of tumors. Furthermore, the depression is more prevalent among patients who have been treated with radiation. Patients in the head and neck group who have received transfer factor show an initial decreased response to PHA stimulation in culture. This is not seen in a control group of head and neck cancer patients or in patients with nonsquamous cander. Thymus-derived lymphocytes are depressed in patients with head and neck cancer, irrespective of whether they have received radiation. Th T-lymphocyte levels increased in eight of 38 patients who received nonimmune transfer factor, but 7 of these were in the group who had not received radiation. The leu kocyte adherence inhibition (LAI) test has been used to determine tumor immunity in the patient test group. Changes in tumor immunity did not occur in those patients who received normal nonimmune transfer factor. Studies are presently in progress which provide for treatment of patients with head and neck cancer with specific squamous carcinoma immune transfer factor.
